Sulfonylurea Compounds

• 

  Subject Areas on Research

  • A retrospective cohort study of economic outcomes and adherence to monotherapy with metformin, pioglitazone, or a sulfonylurea among patients with type 2 diabetes mellitus in the United States from 2003 to 2005. 
  • Are sulfonylureas passé? 
  • Association of Systemic Medication Use With Intraocular Pressure in a Multiethnic Asian Population: The Singapore Epidemiology of Eye Diseases Study. 
  • Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. 
  • Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. 
  • Capitalizing on prescribing pattern variation to compare medications for type 2 diabetes. 
  • Capsule Commentary on Min et al., Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes: How to Escalate Therapy for Patients who Fail Sulfonylureas. 
  • Cardiovascular and Other Outcomes Postintervention With Insulin Glargine and Omega-3 Fatty Acids (ORIGINALE). 
  • Combination insulin-sulfonylurea therapy in type II diabetes mellitus. 
  • Cryptococcus neoformans Ilv2p confers resistance to sulfometuron methyl and is required for survival at 37 degrees C and in vivo. 
  • Determinants of weight gain in the action to control cardiovascular risk in diabetes trial. 
  • Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. 
  • Growth inhibition of pathogenic bacteria by sulfonylurea herbicides. 
  • HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. 
  • Insulin resistance in patients with insulin independent diabetes mellitus: partial amelioration by the sulfonylurea glipizide. 
  • Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. 
  • Long-term safety and efficacy of glipizide. 
  • Mechanism of action of the second-generation sulfonylurea glipizide. 
  • Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. 
  • New anticancer agents. 
  • Oral agent therapy in the treatment of type 2 diabetes. 
  • Oral agents in the management of type 2 diabetes mellitus. 
  • Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin. 
  • Potentiation of insulin action: a probable mechanism for the anti-diabetic action of sulfonylurea drugs. 
  • Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease. 
  • Recombinant glucagon-like peptide-1 (7-36 amide) lowers fasting serum glucose in a broad spectrum of patients with type 2 diabetes. 
  • Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. 
  • Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. 
  • Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. 
  • Sulfonylurea drugs and insulin-independent diabetes mellitus. 
  • Sulfonylurea drugs: mechanism of antidiabetic action and therapeutic usefulness. 
  • Sulfonylurea signal transduction. 
  • Sulfonylurea treatment of insulin-independent diabetes mellitus. 
  • Sulphonylureas increase the number of insulin receptors. 
  • The benefit of increasing sulfonylurea dose. 
  • The use of insulin secretagogues in the treatment of type 2 diabetes. 
  • Treatment of diabetes mellitus: implications of the use of oral agents. 
  • Treatment of poorly regulated non-insulin-dependent diabetes mellitus with combination insulin-sulfonylurea. 
  • Treatment of type 2 diabetes mellitus. 
  • β-Cell-intrinsic β-arrestin 1 signaling enhances sulfonylurea-induced insulin secretion.